Compound reference
CJC-1295 DAC
Growth Hormone Research · vial. For laboratory research use only. Not for human or veterinary consumption, diagnostic use, therapeutic use, or clinical use.
Chemistry identity
Reference identifiers
COA documentation
Lot record status
COA on file - lab confirmation pendingView Lab ReportsPublished literature
Research context
Peer-reviewed literature referencing this compound, provided for research context.
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry2026
Uçaktürk E, Nemutlu E
Journal of pharmaceutical and biomedical analysis
A 2025 analytical chemistry study developed and validated a nano-liquid chromatography-Orbitrap mass spectrometry method capable of detecting CJC-1295 and related GHRH analogs at sub-nanogram-per-milliliter concentrations in urine matrices, establishing a sensitive research assay for peptide identification and quantification.
Advances in the detection of growth hormone releasing hormone synthetic analogs2021
Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V
Drug testing and analysis
A 2021 in vitro metabolism study characterized major degradation metabolites of CJC-1295 and CJC-1295 with Drug Affinity Complex generated in fortified urine, using synthesized reference metabolites to build a liquid chromatography-tandem mass spectrometry assay for peptide detection research.
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse2006
Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, et al.
American journal of physiology. Endocrinology and metabolism
A 2006 study in GHRH-knockout mice examined once-daily versus less-frequent administration of the long-acting GHRH analog CJC-1295, finding that daily administration normalized body weight, length, and pituitary GH mRNA expression, with immunohistochemistry showing somatotroph cell proliferation -- establishing CJC-1295's mechanism of sustained GHRH-receptor engagement in a rodent model of GH deficiency.
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog2005
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al.
Endocrinology
The foundational 2005 study describing CJC-1295 synthesis used cultured rat anterior pituitary cells to demonstrate that albumin-bioconjugated GHRH(1-29) analogs retain bioactivity and resist dipeptidyl peptidase-IV degradation, then confirmed in Sprague-Dawley rats that CJC-1295 covalently binds circulating albumin and extends measurable GH-secretion activity beyond 72 hours post-injection.
Catalog access requires an account and acceptance of a research-use disclaimer.
This product is intended strictly for research and laboratory use only. It is designated for in vitro testing and experimental purposes. Any use involving human or animal consumption is prohibited by law. All information provided on this website is for educational purposes only. This product must only be handled by licensed, qualified professionals. It is not intended for use as a drug, food, or cosmetic, and must not be misused, mislabeled, or misrepresented as such.